Carolyn Nickson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Carolyn Nickson has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
- Anne Marie Kavanagh
University of Melbourne, Melbourne, Australia
10 shared publications - Gregory Bruce Mann
The Breast Service, The Royal Melbourne Hospital, Parkville, Australia
10 shared publications - Louiza S. Velentzis
The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney 2006, NSW, Australia
7 shared publications - Jie-Bin Lew
Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
6 shared publications - Dallas R. English
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
5 shared publications Karen Canfell
School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney 2006, NSW, Australia
5 shared publications
Latest Publications
- Open Access
- 19 March 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 57, 101520
Risk-adjusted breast screening: an Australian perspective and considerations for the Western Pacific
- 19 March 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 57, 101520
Open AccessRisk-adjusted breast screening: an Australian perspective and considerations for the Western Pacific
- Open Access
Reduced Breast and Ovarian Cancer Through Targeted Genetic Testing: Estimates Using the NEEMO Microsimulation Model
Background: The effectiveness and cost-effectiveness of genetic testing for hereditary breast and ovarian cancer largely rely on the identification and clinical management of individuals with a pathogenic variant prior to developing cancer. Simulation modelling is commonly utilised to evaluate genetic testing strategies due to its ability to synthesise collections of data and extrapolate over long time periods and large populations. Existing genetic testing simulation models use simplifying assumptions for predictive genetic testing and risk management uptake, which could impact the reliability of their estimates. Our objective was to develop a microsimulation model that accurately reflects current genetic testing and subsequent care in Australia, directly incorporating the dynamic nature of predictive genetic testing within families and adherence to cancer risk management recommendations. Methods: The populatioN gEnEtic testing MOdel (NEEMO) is a population-level microsimulation that incorporates a detailed simulation of individuals linked within five-generation family units. The genetic component includes heritable high- and moderate-risk monogenic gene variants, as well as polygenic risk. Interventions include clinical genetic services, breast screening, and risk-reducing surgery. Model validation is described, and then to illustrate a practical application, NEEMO was used to compare clinical outcomes for four genetic testing scenarios in patients newly diagnosed with breast cancer (BC) and their relatives: (1) no genetic testing, (2) current practice, (3) optimised referral for genetic testing, and (4) genetic testing for all BC. Results: NEEMO accurately estimated genetic testing utilisation according to current practice and associated cancer incidence, pathology, and survival. Predictive testing uptake in first- and second-degree relatives was consistent with known prospective genetic testing data. Optimised genetic referral and expanded testing prevented up to 9.3% of BC and 4.1% of ovarian cancers in relatives of patients with BC. Expanding genetic testing eligibility to all BC patients did not lead to improvement in life-years saved in at-risk relatives compared to optimised referral of patients eligible for testing under current criteria. Conclusions: NEEMO is an adaptable and validated microsimulation model for evaluating genetic testing strategies. It captures the real-world uptake of clinical and predictive genetic testing and recommended cancer risk management, which are important considerations when considering real-world clinical and cost-effectiveness.
Open AccessReduced Breast and Ovarian Cancer Through Targeted Genetic Testing: Estimates Using the NEEMO Microsimulation Model
Background: The effectiveness and cost-effectiveness of genetic testing for hereditary breast and ovarian cancer largely rely on the identification and clinical management of individuals with a pathogenic variant prior to developing cancer. Simulation modelling is commonly utilised to evaluate genetic testing strategies due to its ability to synthesise collections of data and extrapolate over long time periods and large populations. Existing genetic testing simulation models use simplifying assumptions for predictive genetic testing and risk management uptake, which could impact the reliability of their estimates. Our objective was to develop a microsimulation model that accurately reflects current genetic testing and subsequent care in Australia, directly incorporating the dynamic nature of predictive genetic testing within families and adherence to cancer risk management recommendations. Methods: The populatioN gEnEtic testing MOdel (NEEMO) is a population-level microsimulation that incorporates a detailed simulation of individuals linked within five-generation family units. The genetic component includes heritable high- and moderate-risk monogenic gene variants, as well as polygenic risk. Interventions include clinical genetic services, breast screening, and risk-reducing surgery. Model validation is described, and then to illustrate a practical application, NEEMO was used to compare clinical outcomes for four genetic testing scenarios in patients newly diagnosed with breast cancer (BC) and their relatives: (1) no genetic testing, (2) current practice, (3) optimised referral for genetic testing, and (4) genetic testing for all BC. Results: NEEMO accurately estimated genetic testing utilisation according to current practice and associated cancer incidence, pathology, and survival. Predictive testing uptake in first- and second-degree relatives was consistent with known prospective genetic testing data. Optimised genetic referral and expanded testing prevented up to 9.3% of BC and 4.1% of ovarian cancers in relatives of patients with BC. Expanding genetic testing eligibility to all BC patients did not lead to improvement in life-years saved in at-risk relatives compared to optimised referral of patients eligible for testing under current criteria. Conclusions: NEEMO is an adaptable and validated microsimulation model for evaluating genetic testing strategies. It captures the real-world uptake of clinical and predictive genetic testing and recommended cancer risk management, which are important considerations when considering real-world clinical and cost-effectiveness.
- Open Access
- 7 August 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (17) , 18120-18132
Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
Background: Quantifying the benefits and harms of breast cancer screening accurately is important for planning and evaluating screening programs and for enabling women to make informed decisions about participation. However, few cohort studies have attempted to estimate benefit and harm simultaneously.Aims: We aimed to quantify the impact of mammographic screening on breast cancer mortality and overdiagnosis using a cohort of women invited to attend Australia's national screening program, BreastScreen.Methods: In a cohort of 41,330 women without prior breast cancer diagnosis, screening, or diagnostic procedures invited to attend BreastScreen Western Australia in 1994‐1995, we estimated the cumulative risk of breast cancer mortality and breast cancer incidence (invasive and ductal carcinoma in situ) from age 50 to 85 years for attenders and non‐attenders. Data were obtained by linking population‐based state and national health registries. Breast cancer mortality risks were estimated from a survival analysis that accounted for competing risk of death from other causes. Breast cancer risk for unscreened women was estimated by survival analysis, while accounting for competing causes of death. For screened women, breast cancer risk was the sum of risk of being diagnosed at first screen, estimated using logistic regression, and risk of diagnosis following a negative first screen estimated from a survival analysis.Results: For every 1,000 women 50 years old at first invitation to attend BreastScreen, there were 20 (95% CI 12‐30) fewer breast cancer deaths and 25 (95% CI 15‐35) more breast cancers diagnosed for women who attended than for non‐attendees by age 85. Of the breast cancers diagnosed in screened women, 21% (95% CI 13%‐27%) could be attributed to screening.Discussion: The estimated ratio of benefit to harm was consistent with, but slightly less favourable to screening than most other estimates from cohort studies.Conclusion: Women who participate in organised screening for breast cancer in Australia have substantially lower breast cancer mortality, while some screen‐detected cancers may be overdiagnosed.
- 7 August 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (17) , 18120-18132
Open AccessBenefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
Background: Quantifying the benefits and harms of breast cancer screening accurately is important for planning and evaluating screening programs and for enabling women to make informed decisions about participation. However, few cohort studies have attempted to estimate benefit and harm simultaneously.Aims: We aimed to quantify the impact of mammographic screening on breast cancer mortality and overdiagnosis using a cohort of women invited to attend Australia's national screening program, BreastScreen.Methods: In a cohort of 41,330 women without prior breast cancer diagnosis, screening, or diagnostic procedures invited to attend BreastScreen Western Australia in 1994‐1995, we estimated the cumulative risk of breast cancer mortality and breast cancer incidence (invasive and ductal carcinoma in situ) from age 50 to 85 years for attenders and non‐attenders. Data were obtained by linking population‐based state and national health registries. Breast cancer mortality risks were estimated from a survival analysis that accounted for competing risk of death from other causes. Breast cancer risk for unscreened women was estimated by survival analysis, while accounting for competing causes of death. For screened women, breast cancer risk was the sum of risk of being diagnosed at first screen, estimated using logistic regression, and risk of diagnosis following a negative first screen estimated from a survival analysis.Results: For every 1,000 women 50 years old at first invitation to attend BreastScreen, there were 20 (95% CI 12‐30) fewer breast cancer deaths and 25 (95% CI 15‐35) more breast cancers diagnosed for women who attended than for non‐attendees by age 85. Of the breast cancers diagnosed in screened women, 21% (95% CI 13%‐27%) could be attributed to screening.Discussion: The estimated ratio of benefit to harm was consistent with, but slightly less favourable to screening than most other estimates from cohort studies.Conclusion: Women who participate in organised screening for breast cancer in Australia have substantially lower breast cancer mortality, while some screen‐detected cancers may be overdiagnosed.
- Open Access
- 6 April 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia
Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020–2021) and colorectal cancer (up to 12.1% reduction over 2020–21), and increase cervical cancer diagnoses (up to 3.6% over 2020–2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6–12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions.
- 6 April 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessA modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia
Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020–2021) and colorectal cancer (up to 12.1% reduction over 2020–21), and increase cervical cancer diagnoses (up to 3.6% over 2020–2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6–12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions.
- Open Access
- 17 March 2023
- Published by Elsevier in The Breast
- Vol. 68, 239
Contrast Enhanced Mammography In Breast Cancer Surveillance
- 17 March 2023
- Published by Elsevier in The Breast
- Vol. 68, 239
Open AccessContrast Enhanced Mammography In Breast Cancer Surveillance
- Open Access
- 17 March 2023
- Published by Elsevier in The Breast
- Vol. 68, 235
Contrast Enhanced Mammography In Further Assessment Of Screen-Detected Breast Cancer
- 17 March 2023
- Published by Elsevier in The Breast
- Vol. 68, 235
Open AccessContrast Enhanced Mammography In Further Assessment Of Screen-Detected Breast Cancer
- Open Access
Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review
Background: The benefits and harms of breast screening may be better balanced through a risk-stratified approach. We conducted a systematic review assessing the accuracy of questionnaire-based risk assessment tools for this purpose. Methods: Population: asymptomatic women aged ≥40 years; Intervention: questionnaire-based risk assessment tool (incorporating breast density and polygenic risk where available); Comparison: different tool applied to the same population; Primary outcome: breast cancer incidence; Scope: external validation studies identified from databases including Medline and Embase (period 1 January 2008–20 July 2021). We assessed calibration (goodness-of-fit) between expected and observed cancers and compared observed cancer rates by risk group. Risk of bias was assessed with PROBAST. Results: Of 5124 records, 13 were included examining 11 tools across 15 cohorts. The Gail tool was most represented (n = 11), followed by Tyrer-Cuzick (n = 5), BRCAPRO and iCARE-Lit (n = 3). No tool was consistently well-calibrated across multiple studies and breast density or polygenic risk scores did not improve calibration. Most tools identified a risk group with higher rates of observed cancers, but few tools identified lower-risk groups across different settings. All tools demonstrated a high risk of bias. Conclusion: Some risk tools can identify groups of women at higher or lower breast cancer risk, but this is highly dependent on the setting and population.
Open AccessBreast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review
Background: The benefits and harms of breast screening may be better balanced through a risk-stratified approach. We conducted a systematic review assessing the accuracy of questionnaire-based risk assessment tools for this purpose. Methods: Population: asymptomatic women aged ≥40 years; Intervention: questionnaire-based risk assessment tool (incorporating breast density and polygenic risk where available); Comparison: different tool applied to the same population; Primary outcome: breast cancer incidence; Scope: external validation studies identified from databases including Medline and Embase (period 1 January 2008–20 July 2021). We assessed calibration (goodness-of-fit) between expected and observed cancers and compared observed cancer rates by risk group. Risk of bias was assessed with PROBAST. Results: Of 5124 records, 13 were included examining 11 tools across 15 cohorts. The Gail tool was most represented (n = 11), followed by Tyrer-Cuzick (n = 5), BRCAPRO and iCARE-Lit (n = 3). No tool was consistently well-calibrated across multiple studies and breast density or polygenic risk scores did not improve calibration. Most tools identified a risk group with higher rates of observed cancers, but few tools identified lower-risk groups across different settings. All tools demonstrated a high risk of bias. Conclusion: Some risk tools can identify groups of women at higher or lower breast cancer risk, but this is highly dependent on the setting and population.
- Open Access
- 3 February 2022
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 46 (2) , 230-236
BreastScreen Australia national data by factors of interest for risk‐based screening: routinely reported data and opportunities for enhancement
- 3 February 2022
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 46 (2) , 230-236
Open AccessBreastScreen Australia national data by factors of interest for risk‐based screening: routinely reported data and opportunities for enhancement
- Open Access
- 1 September 2021
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 50 (Supplement)
965The estimated impact of improved breast screening tests targeted at women with dense breasts
Background: There is increasing interest in risk-based breast cancer screening, including interventions to improve outcomes for women with mammographically dense breasts. Methods: Policy1-Breast is a continuous-time, multiple-cohort micro-simulation whole-population model which incorporates breast cancer risk, life-course breast density, menopause, hormone therapy use and screening participation. Outcomes include cancer diagnoses and characteristics (invasive/DCIS, tumour size, grade), mode of detection (screen-detected/interval/other) and mortality (breast cancer and other cause). Policy1-Breast validates well against key observed clinical outcomes in Australia. We estimate changes in outcomes within and outside the BreastScreen program upon the introduction of a hypothetical screening test with improved sensitivity for women with dense breasts. Results: We estimate that introducing in year 2020 a screening test for women in the highest quintile of breast density at age 50 that halves the masking effect of their breast density would, by 2026-2030, increase diagnosis rates of population-level invasive cancers ( 10%) and screen-detected cancers (20%) and decrease rates of interval cancers (17%) and community-detected cancers (6%). Conclusions: Targeted screening tests with improved sensitivity for women with dense breasts are expected to markedly reduce interval cancers and other cancers diagnosed outside the BreastScreen program, while increasing all cancer diagnoses due to increased rates of screen-detected cancers. Key messages: Specialised breast cancer screening tests directed at women with very high breast density are expected to reduce interval cancers and increase overall cancer diagnoses. Population simulation models such as Policy1-Breast can complement trial evidence by evaluating a range of scenarios and estimating short and long-term implications.
- 1 September 2021
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 50 (Supplement)
Open Access965The estimated impact of improved breast screening tests targeted at women with dense breasts
Background: There is increasing interest in risk-based breast cancer screening, including interventions to improve outcomes for women with mammographically dense breasts. Methods: Policy1-Breast is a continuous-time, multiple-cohort micro-simulation whole-population model which incorporates breast cancer risk, life-course breast density, menopause, hormone therapy use and screening participation. Outcomes include cancer diagnoses and characteristics (invasive/DCIS, tumour size, grade), mode of detection (screen-detected/interval/other) and mortality (breast cancer and other cause). Policy1-Breast validates well against key observed clinical outcomes in Australia. We estimate changes in outcomes within and outside the BreastScreen program upon the introduction of a hypothetical screening test with improved sensitivity for women with dense breasts. Results: We estimate that introducing in year 2020 a screening test for women in the highest quintile of breast density at age 50 that halves the masking effect of their breast density would, by 2026-2030, increase diagnosis rates of population-level invasive cancers ( 10%) and screen-detected cancers (20%) and decrease rates of interval cancers (17%) and community-detected cancers (6%). Conclusions: Targeted screening tests with improved sensitivity for women with dense breasts are expected to markedly reduce interval cancers and other cancers diagnosed outside the BreastScreen program, while increasing all cancer diagnoses due to increased rates of screen-detected cancers. Key messages: Specialised breast cancer screening tests directed at women with very high breast density are expected to reduce interval cancers and increase overall cancer diagnoses. Population simulation models such as Policy1-Breast can complement trial evidence by evaluating a range of scenarios and estimating short and long-term implications.
- 27 January 2021
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 21 (4) , 847-857
Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer
Background: Although evaluations of breast cancer screening programs frequently estimate quality-adjusted life-year (QALY) losses by stage, other breast cancer characteristics influence treatment and vary by mode of detection – i.e. whether the cancer is detected through a screening program (screen-detected), in between screening rounds (interval-detected) or outside the screening program (community-detected). Here, we estimate the association between early-stage invasive breast cancer (ESIBC) characteristics and treatment-related QALY losses. Methods: Using clinicopathological and treatment information from 675 women managed for ESIBC, we estimated the average five-year treatment-related QALY loss by detection group. We then used regression analysis to estimate the extent to which known cancer characteristics and the mode of detection, are associated with treatment and treatment-related QALY losses. Results: Community-detected cancers had the largest average QALY loss (0.76 QALYs [95%CI 0.73;0.80]), followed by interval-detected cancers (0.75 QALYs [95%CI 0.68;0.82]) and screen-detected cancers (0.69 QALYs [95%CI 0.67;0.71]). Adverse prognostic factors more common in community-detected and interval-detected breast cancers (large tumour sizes, lymph node involvement, high grade) were largely associated with QALY losses from mastectomies and chemotherapy. Receptor positive subtypes, more common in screen-detected cancers, were associated with QALY losses related to endocrine therapy. Conclusions: The associations between ESIBC characteristics and treatment-related QALY losses should be considered when evaluating breast cancer screening and treatment strategies.
- 27 January 2021
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 21 (4) , 847-857
Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer
Background: Although evaluations of breast cancer screening programs frequently estimate quality-adjusted life-year (QALY) losses by stage, other breast cancer characteristics influence treatment and vary by mode of detection – i.e. whether the cancer is detected through a screening program (screen-detected), in between screening rounds (interval-detected) or outside the screening program (community-detected). Here, we estimate the association between early-stage invasive breast cancer (ESIBC) characteristics and treatment-related QALY losses. Methods: Using clinicopathological and treatment information from 675 women managed for ESIBC, we estimated the average five-year treatment-related QALY loss by detection group. We then used regression analysis to estimate the extent to which known cancer characteristics and the mode of detection, are associated with treatment and treatment-related QALY losses. Results: Community-detected cancers had the largest average QALY loss (0.76 QALYs [95%CI 0.73;0.80]), followed by interval-detected cancers (0.75 QALYs [95%CI 0.68;0.82]) and screen-detected cancers (0.69 QALYs [95%CI 0.67;0.71]). Adverse prognostic factors more common in community-detected and interval-detected breast cancers (large tumour sizes, lymph node involvement, high grade) were largely associated with QALY losses from mastectomies and chemotherapy. Receptor positive subtypes, more common in screen-detected cancers, were associated with QALY losses related to endocrine therapy. Conclusions: The associations between ESIBC characteristics and treatment-related QALY losses should be considered when evaluating breast cancer screening and treatment strategies.